European Thyroid Association (ETA) and Thyroid Federation International (TFI) Joint Position Statement on the Interchangeability of Levothyroxine Products in EU Countries

被引：21

作者：

Fliers, Eric ^{[1
]}

Demeneix, Barbara ^{[2
]}

Bhaseen, Ashok

Brix, Thomas H. ^{[3
]}

机构：

[1] Univ Amsterdam, Dept Endocrinol & Metab, Med Ctr, Locat AMC, Amsterdam, Netherlands

[2] CNRS, UMR 7221, Evolut Regulat Endocriniennes, Museum Natl Hist Nat,Dept Adaptat Vivant, Paris, France

[3] Odense Univ Hosp, Dept Endocrinol & Metab, Sonder Blvd 29, DK-5000 Odense C, Denmark

来源：

EUROPEAN THYROID JOURNAL | 2018年 / 7卷 / 05期

关键词：

Levothyroxine products; Health issues; European Thyroid Association; Thyroid Federation International;

D O I：

10.1159/000493123

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Several European countries have seen major health issues after a switch from one levothyroxine brand to another, as well as following the introduction of several levothyroxine formulation changes. While the relationship between these health issues and brand or formulation changes merits further investigation, the current position statement on behalf of both health-care providers and patients summarizes recent events in several European countries and provides a number of recommendations to limit the burden for patients, so as to prevent increased health-care consumption and health-care expenses in this context. (C) 2018 European Thyroid Association Published by S. Karger AG, Basel

引用

页码：238 / 242

页数：5

共 3 条

[1]

American Thyroid Association, 2004, Thyroid, V14, P486

[2] Doubling in the use of thyroid hormone replacement therapy in Denmark: association to iodization of salt? [J].